LIVASSURED

What LIVASSURED does

LIVASSURED B.V. is a Netherlands-based private medical device company founded in 2013 that develops and produces NightWatch+, an EU MDR Class IIa certified wearable seizure detection system for nocturnal epilepsy monitoring. The product consists of a wireless arm-worn sensor that continuously monitors heart rate and movement during sleep, paired with a base station and the cloud-hosted NightWatch Portal that delivers caregiver notifications when tonic-clonic, tonic (clustered/prolonged), hyperkinetic, or myoclonic (clustered) seizures are detected. The proprietary detection algorithm was co-developed with a Dutch consortium of neurologists, patient organizations, universities, and high-tech firms, and has been clinically validated by the Dutch Epilepsy Center SEIN and the Academic Center for Epileptology at Kempenhaeghe over thousands of patient nights, with reported sensitivity of 86% (adults) and 100% (children) for major motor seizure types and 96%/100% for tonic-clonic seizures.

The business model is primarily hardware sales of the NightWatch+ device, sold directly to patients and caregivers via the company's website (with a 30-day trial and quote-based pricing) and to residential care facilities, with the latter supporting nurse call system integration. The NightWatch Portal is currently bundled free with device purchase, providing detailed sensor data and alarm history; the architecture supports future subscription or premium service revenue, but no recurring stream is disclosed. The company markets to two primary segments — epilepsy patients (4+) with nocturnal motor seizures and their caregivers — and a secondary segment of residential care facilities, leveraging clinical validation, scientific publications, and patient testimonials as primary GTM assets across six European languages.

LIVASSURED operates with 11-50 employees from Leiden, the Netherlands, manufactures under ISO 13485, claims a base of 10,000+ families, and sells primarily across Europe (NL, EN-US, FR, DE, IT, ES). Ownership is private with no disclosed external investors, funding rounds, or M&A activity; the company runs as an independent B.V. without a publicly disclosed revenue figure. Strategic positioning is that of a focused, clinically validated niche medical device player in the nocturnal epilepsy monitoring category, with EU regulatory clearance functioning as its principal barrier to entry.

Name

LIVASSURED

Legal name

LivAssured B.V.

Website

https://livassured.nl

Company type

Private

Founded year

2013

Operating status

Operating

Headcount range

11–50 employees

Short description

LIVASSURED B.V. is a Netherlands-based medical device company that develops and sells NightWatch+, an EU MDR Class IIa certified wearable arm sensor that detects dangerous nocturnal epileptic seizures in real time and alerts caregivers, clinically validated by Dutch epilepsy centers and sold direct to families and residential care facilities across Europe.

Ownership category

akta.pro rank

Product category

Wearable Medical Devices

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)

SIC

Surgical & Medical Instruments & Apparatus (3841), Services-Home Health Care Services (8082)

akta.pro industry

PRIMARYHLAHACAE

Neurological Monitoring (EEG, Seizure/Sleep/Neuro Wearables)

Healthcare & Life Sciences/Medical Devices & Diagnostics/Patient Monitoring, Wearables & Remote Diagnostics

SECONDARYHLACAPAF

Elder Care, Assisted Living & Fall Detection Systems

Healthcare & Life Sciences/Digital Health & Health IT/Healthcare IoT & Remote Patient Monitoring

SECONDARYHSABAKAE

Home Patient Monitoring & Telehealth Devices (Vitals, Fall Detection, PERS)

Home & Personal Services/Elder Care & In-Home Care Services/Medical Equipment & Home Mobility Support Services

Keywords

• Wearable seizure detection
• Epilepsy monitoring devices
• Nocturnal seizure alerts
• Medical wearable sensors
• Neurological diagnostic devices

Headquarters

HQ city

Leiden

HQ country

Netherlands

HQ region

Europe

Offices1 record

Markets served

GTM type

B2C

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Supply Chain, Personnel, Operations, Marketing or Sales

Revenue model

1. NightWatch+ Medical Device Sales: Sale of the NightWatch+ hardware device - a wearable sensor and base station system for epilepsy seizure detection during sleep. The product is a Class IIa medical device sold directly to patients, caregivers, and residential care facilities.
2. NightWatch Portal Subscription: Free access to the NightWatch portal is included with device purchase, providing seizure monitoring and data insights. Potential recurring revenue through portal services or premium features.

Pricing tiers

Go-to-market motion1 record

Distribution channels2 records

Marketing channels7 records

Core offering

LIVASSURED develops and sells the NightWatch+ system, a Class IIa medical device comprising a wireless arm-worn sensor and base station that continuously monitors heart rate and movements during sleep to detect dangerous nocturnal epileptic seizures. The system is intended for epilepsy patients aged 4 and older with motor seizures and is sold directly to patients, caregivers, and residential care facilities, complemented by the free NightWatch Portal for caregiver monitoring.

Product overview

LIVASSURED offers a single unified product: NightWatch+, an AI-driven wearable epilepsy seizure detection system designed for nocturnal monitoring. The system consists of a wireless arm-worn sensor that continuously monitors heart rate and movements during sleep, paired with a base station that alerts caregivers when dangerous seizures are detected. NightWatch+ is complemented by the NightWatch Portal, a web-based monitoring tool that provides caregivers with detailed sensor data and seizure alarm insights. The company develops and produces the device in the Netherlands as a Class IIa medical device under EU MDR regulations.

Differentiator

Problem solved

Functional benefit

Brands

• NightWatch+: Epilepsy seizure detection system designed to detect dangerous nocturnal seizures during sleep. Includes a wireless sensor that monitors heart rate and movements, with clinical validation showing 86% median sensitivity for adults and 100% for children for major motor seizure types.

Products and services

• NightWatch+ Class IIa medical device comprising a wireless arm-worn sensor and base station that continuously monitors heart rate and movement during sleep to detect tonic-clonic, tonic (clustered/prolonged), hyperkinetic, and myoclonic (clustered) seizures in epilepsy patients aged 4 and older. When a potentially dangerous seizure is detected, the base station issues audio and visual alarms to notify a caregiver at home or in a residential care facility.
• NightWatch Portal Internet-connected web portal bundled with NightWatch+ that gives caregivers and clinicians access to detailed sensor data, insights into nighttime events, and alarm history to support seizure monitoring, analysis, and care decisions.
• NightWatch+ Replacement Parts and Accessories Replacement components and accessories for the NightWatch+ system available for order through the company website, supporting continued use of the device over time.

Quantifiable outcome

• 86% median sensitivity for all major motor seizure types in adults; 100% in children
• +2 more outcomes

Named customers1 record

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature3 records

Partnerships

Three partnerships are on record, tiered core.

• Dutch Epilepsy Center SEINcoreStrategic or Co-development PartnerSEIN (Stichting Epilepsie Instellingen Nederland) validated the NightWatch+ detection algorithm technology over thousands of nights. Their clinical findings showed the technology to be significantly more effective than alternative technologies. SEIN is a leading Dutch epilepsy center that contributed to the clinical validation of the device's algorithm.
• Academic Center for Epileptology at KempenhaeghecoreStrategic or Co-development PartnerKempenhaeghe, along with SEIN, validated the NightWatch+ detection algorithm technology. The Academic Center for Epileptology contributed to the rigorous clinical validation studies that demonstrated the device's effectiveness for seizure detection in residential and home settings.
• Dutch Consortium (Neurologists, Patient Organisations, Universities, High-tech Industries)coreStrategic or Co-development PartnerNightWatch+ seizure detection technology was invented and developed in collaboration with a consortium of Dutch neurologists, patient organisations, universities, and high-tech industries. This multi-stakeholder development approach contributed to the technology's clinical rigor and market validation.

Scale indicators2 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Empatica: Empatica's Embrace (and EpiMonitor on Apple Watch) is an FDA-cleared wearable that detects generalized tonic-clonic seizures and alerts caregivers. It is the most direct head-to-head competitor to NightWatch+, with similar target customers (epilepsy patients/families), a comparable wearable form factor, and a clinical-validation-led GTM.
• Smart Monitor (Inspyre): Smart Monitor offers the Inspyre watch and bedside sensor for detecting tonic-clonic seizures and alerting caregivers. Direct competitor in nocturnal/home seizure detection with overlapping customer base of epilepsy patients and care facilities.
• Emfit: Emfit produces movement-based bed sensors (including the Emfit QS for tonic-clonic seizure detection during sleep). Direct competitor in the nocturnal home seizure monitoring niche, particularly relevant for caregivers and residential care facilities where contact-less monitoring is preferred.

Emerging players

• EpiTel: EpiTel is developing wearable EEG-based seizure detection technology (the Epitel wearable platform) targeting ambulatory and home monitoring of epileptic seizures. Comparable in product vision (continuous home monitoring) but uses a different sensor modality (EEG vs. NightWatch+'s heart rate/motion), making it a partial/emerging peer rather than a direct head-to-head.
• Brain Sentinel: Brain Sentinel developed the SPEAC system, an FDA-cleared surface EMG wearable for seizure monitoring. Comparable target market (epilepsy patients, clinicians) with an FDA pathway established, though a different sensor modality than NightWatch+.
• Ceribell: Ceribell makes a portable EEG headband and cloud platform for point-of-care brain monitoring, primarily in hospital and emergency settings. Comparable as a neurology wearable with continuous monitoring + cloud portal, though its setting is acute care rather than home epilepsy use.
• iCEWYZE: iCEWYZE is an early-stage wearable neurology play focused on seizure detection. A niche emerging player in the same product category, with overlapping target market but limited scale relative to LIVASSURED.

Broad incumbents

• Medtronic: Medtronic is a major neurotechnology incumbent with diagnostic and monitoring devices across epilepsy (including implanted neurostimulators like the Percept PC). While its core is invasive diagnostics and DBS, its scale, regulatory expertise, and neurology sales channels represent both an aspirational peer and a potential acquirer/competitor for LIVASSURED's market.
• Natus Medical: Natus manufactures neurodiagnostic and monitoring equipment widely used in clinical EEG and epilepsy workup. Overlaps with LIVASSURED in the broader neurology monitoring space, though primarily serves clinical/in-hospital settings rather than home monitoring.
• Philips (Patient Monitoring): Philips operates a large remote patient monitoring and connected care portfolio. Comparable in the broader remote-monitoring category and in care-facility channel access, but does not currently specialize in nocturnal epilepsy seizure detection.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/channel/UCLkY68uX3ifH0Y3Tpo0uaMg
• Facebookfacebook.com/EpilepsySeizureDetectionEN
• LinkedInlinkedin.com/company/nightwatch-epilepsy-detection
• Instagraminstagram.com/epi_nightwatch
• Xx.com/NightWatchAlarm

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about LIVASSURED